logo-loader
viewRecce Pharmaceuticals Ltd

Recce Pharmaceuticals buoyed by preliminary results from SARS-CoV-2 antiviral screening program

The company is pioneering the development and commercialisation of new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce Pharmaceuticals Ltd - Recce Pharmaceuticals buoyed by preliminary results from SARS-CoV-2 antiviral screening program
Recce’s patented lead candidate RECCE 327 is wholly owned and manufactured in Australia.

Recce Pharmaceuticals Ltd (ASX:RCE) has received encouraging results for its antiviral SARS-CoV-2 screening program RECCE 327 (R327) from the Peter Doherty Institute for Infection and Immunology that shows that it has the ability to prevent the growth of the SARS-CoV-2 virus.

According to the company, R327 has shown encouraging inhibition and is advancing to Stage 1b, which is to begin in a few weeks at the Doherty Institute in Melbourne.

“Highly encourage by the results”

Recce non-executive chairman John Prendergast said: “We’re highly encouraged by the results from this study, which indicate anti-viral activity of R327 and, in particular, highlight the potential potency of our lead candidate against SARS-CoV-2.

“We are interested in seeing the next stage and look forward to continuing research on the effectiveness of R327 with the team at the Doherty Institute.”

Ongoing study in the US

In parallel to the CSIRO and Doherty Institute studies in Australia, a contract research organisation in the US is advancing in their in-vivo studies of RECCE compounds against SARS-CoV-2 in ferrets.

These studies continue to progress well with results on-track for year-end 2020.
According to the company, the engagement of the US organisation has not resulted in any material benefits at this stage, however, if there are any material results from the studies, it will announce later.

Recce’s chief executive officer James Graham outlined the company progress during today’s Proactive Biotech Webinar.

This presentation, along with others by Pharmaxis Ltd (ASX:PXS) and Cynata Therapeutics Ltd (ASX:CYP) can be viewed by clicking this link.

Quick facts: Recce Pharmaceuticals Ltd

Price: 1.08 AUD

ASX:RCE
Market: ASX
Market Cap: $187.61 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Recce Pharmaceuticals Ltd named herein, including the promotion by the Company of Recce Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Recce Pharmaceuticals on track to develop synthetic antibiotics targeting...

Recce Pharmaceuticals Ltd (ASX:RCE) executive director James Graham tells Proactive Investors the company is on the verge of developing a new class of synthetic antibiotics to counter antibiotic resistance.   As fears of superbugs may one day reach pandemic proportions, Graham...

on 29/5/19

2 min read